Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
5 p, 324.7 KB The European Cancer Patient's Bill of Rights, update and implementation 2016 / Højgaard, Liselotte (Kobenhavns Universitet) ; Löwenberg, Bob (Erasmus University Medical Center) ; Selby, Peter (University of Leeds) ; Lawler, Mark (European Cancer Concord) ; Banks, Ian (University of Leeds) ; Law, Kate (European Cancer Concord) ; Albreht, Tit (Institut za varovanje zdravja Republike Slovenija) ; Armand, Jean-Pierre (Gustave Roussy) ; Barbacid, Mariano (Centro Nacional de Investigaciones Oncológicas) ; Barzach, Michèle (IHU Strasbourg Board of Trustees) ; Bergh, Jonas (Karolinska Institutet (Estocolm, Suècia)) ; Cameron, David (University of Edinburgh) ; Conte, Pierfranco (Istituto Oncologico Veneto) ; de Braud, Filippo (National Cancer Institute) ; de Gramont, Aimery (Institut Hospitalier Franco-Britannique) ; De Lorenzo, Francesco (European Cancer Patient Coalition) ; Diehl, Volker (Universität zu Köln) ; Diler, Sarper (Myeloma Patients Europe) ; Erdem, Sema (Europa Donna) ; Geissler, Jan (European Patients Academy on Therapeutic Innovation) ; Gore-Booth, Jola (EuropaColon) ; Henning, Geoffrey (EuropaColon) ; Horgan, Denis (European Alliance for Personalised Medicine) ; Jassem, Jacek (Medical University of Gdansk) ; Johnson, Peter (Cancer Research UK) ; Kaasa, Stein (Norges Teknisk-Naturvitenskapelige Universitet) ; Kapitein, Peter (Inspire2Live) ; Karjalainen, Sakari (Association of European Cancer Leagues) ; Kelly, Joan (Irish Cancer Society) ; Kienesberger, Anita (Austrian Childhood Cancer Organisation) ; La Vecchia, Carlo (Universita degli Studi di Milano) ; Lacombe, Denis (European Organisation for Research and Treatment of Cancer) ; Lindahl, Tomas (Francis Crick Institute) ; Luzzatto, Lucio (Universita degli Studi di Firenze) ; Malby, Rebecca (London South Bank University) ; Mastris, Ken (Europa Uomo) ; Meunier, Françoise (European Organisation for Research and Treatment of Cancer) ; Murphy, Martin (Society for Translational Oncology) ; Naredi, Peter (European Cancer Organisation) ; Nurse, Paul (Francis Crick Institute) ; Oliver, Kathy (International Brain Tumour Alliance) ; Pearce, Jonathan (Lymphoma Association) ; Pelouchov, Jana (European Cancer Patient Coalition) ; Piccart, Martine (Institut Jules Bordet) ; Pinedo, Bob (VuMC Cancer Center) ; Spurrier-Bernard, Gilly (Melanoma Patient Network Europe) ; Sullivan, Richard (Kings Health Partners Integrated Cancer Centre) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Van de Velde, Cornelis (Leids Universitair Medisch Centrum) ; van Herk, Bert (Spaarne Gasthuis) ; Vedsted, Peter (Aarhus Universitet) ; Waldmann, Anita (Leukaemiehilfe RHEIN-MAIN) ; Weller, David (University of Edinburgh) ; Wilking, Nils (Skåne University Hospital (Suècia)) ; Wilson, Roger (Sarcoma Patients EuroNet EV) ; Yared, Wendy (Association of European Cancer Leagues) ; Zielinski, Christoph C (European Society for Medical Oncology) ; zur Hausen, Harald (University of Heidelberg) ; Le Chevalier, Thierry (Institute Gustave Roussy) ; Johnston, Patrick (European Cancer Concord) ; Universitat Autònoma de Barcelona
In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative: The key aspects of working towards implementing the BoR are:.
2017 - 10.1136/esmoopen-2016-000127
ESMO open, Vol. 1 (january 2017)  
2.
14 p, 4.6 MB A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer / Lazar, Vladimir (Gustave-Roussy Cancer Center (France)) ; Rubin, Eitan (Ben-Gurion University of the Negev (Israel)) ; Depil, Stephane (Leon Berard Cancer Center (France)) ; Pawitan, Yudi (Karolinska Institutet (Estocolm, Suècia)) ; Martini, Jean-François (Pfizer Oncology Research (USA)) ; Gomez-Navarro, Jesus (Takeda Pharmaceuticals International Co.(USA)) ; Yver, Antoine (AstraZeneca Pharmaceuticals LP (USA)) ; Kan, Zhengyin (Pfizer Oncology Research (USA)) ; Dry, Jonathan R. (AstraZeneca Pharmaceuticals LP (USA)) ; Kehren, Jeanne (Sanofi (France)) ; Validire, Pierre (Institut Mutualiste Montsouris (France)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vielh, Philippe (Gustave-Roussy Cancer Center (France)) ; Ducreux, Michel (Gustave-Roussy Cancer Center (France)) ; Galbraith, Susan (AstraZeneca Pharmaceuticals LP (USA)) ; Lehnert, Manfred (Takeda Pharmaceuticals International Co. (USA)) ; Onn, Amir (Chaim Sheba Medical Center (Israel)) ; Berger, Raanan (Chaim Sheba Medical Center (Israel)) ; Pierotti, Marco A. (Fondazione IRCCS Istituto Nazionale dei Tumori (Italy)) ; Porgador, Angel (Ben-Gurion University of the Negev (Israel)) ; Pramesh, C. S. (Tata Memorial Centre (India)) ; Ye, Ding-wei (Fudan University Shanghai Cancer Center (China)) ; Carvalho, Andre L. (Barretos Cancer Hospital. Fundacao Pio XII (Brazil)) ; Batist, Gerald (Jewish General Hospita. Segal Cancer Centre (Canada)) ; Le Chevalier, Thierry (Gustave-Roussy Cancer Center (France)) ; Morice, Philippe (Gustave-Roussy Cancer Center (France)) ; Besse, Benjamin (Gustave-Roussy Cancer Center (France)) ; Vassal, Gilles (Gustave-Roussy Cancer Center (France)) ; Mortlock, Andrew (AstraZeneca Pharmaceuticals LP (USA)) ; Hansson, Johan (Karolinska Institutet (Estocolm, Suècia)) ; Berindan Neagoe, Ioana (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Dann, Robert (General Electric Healthcare (USA)) ; Haspel, Joel (Oracle Corporation (UK)) ; Irimie, Alexandru (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Laderman, Steve (Agilent Technologies (USA)) ; Nechushtan, Hovav (Hadassah Hebrew University Medical Center (Israel)) ; Al Omari, Amal S. (King Hussein Cancer Center (Jordan)) ; Haywood, Trent (Blue Cross Blue Shield Association (USA)) ; Bresson, Catherine (WIN Consortium (France)) ; Soo, Khee Chee (National Cancer Centre (Singapore)) ; Osman, Iman (New York University Langone Medical Center (USA)) ; Mata, Hilario (MD Anderson Cancer Center (USA)) ; Lee, Jack J. (MD Anderson Cancer Center (USA)) ; Jhaveri, Komal (New York University Langone Medical Center (USA)) ; Meurice, Guillaume (Gustave-Roussy Cancer Center (France)) ; Palmer, Gary (Foundation Medicine Inc. (USA)) ; Lacroix, Ludovic (Gustave-Roussy Cancer Center (France)) ; Koscielny, Serge (Gustave-Roussy Cancer Center (France)) ; Eterovic, Karina Agda (MD Anderson Cancer Center (USA)) ; Blay, Jean-Yves (Leon Berard Cancer Center (France)) ; Buller, Richard (Pfizer Oncology Research (USA)) ; Eggermont, Alexander (Gustave-Roussy Cancer Center (France)) ; Schilsky, Richard L. (American Society of Clinical Oncology (USA)) ; Mendelsohn, John (MD Anderson Cancer Center (USA)) ; Soria, Jean-Charles (Gustave-Roussy Cancer Center (France)) ; Rothenberg, Mace (Pfizer Oncology Research (USA)) ; Scoazec, Jean-Yves (Gustave-Roussy Cancer Center (France)) ; Ki Hong, Waun (MD Anderson Cancer Center (USA)) ; Kurzrock, Razelle (Moores Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel strategy for identifying customized combinations of triplets of targeted agents, utilizing a simplified interventional mapping system (SIMS) that merges knowledge about existent drugs and their impact on the hallmarks of cancer. [...]
2015 - 10.18632/oncotarget.3741
Oncotarget, Vol. 6, no. 16 (June 2015) , p. 14139-14152  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.